

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 CFR 1.56, 1.97, and 1.98) SHEET 1 OF 1	ATTORNEY DOCKET TLIK-028/01 US	APPLICATION NO. 09/903,442
	APPLICANT(S) Lawrence M. Kauvar, et al.	
	FILING DATE February 27, 2002	GROUP 1619

### U.S. PATENT DOCUMENTS

† EXR INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

### FOREIGN PATENT DOCUMENTS

† EXR INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION/ NOTES
	1A	WO	00/44366	08/2000	Telik, Inc.	

### OTHER DOCUMENTS

† EXR INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	2A	Z. Pavelic et al., "Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir", Poster Abstract; 1 April 2003; obtained from <a href="http://www.dekker.com/servlet/product/DOI/101081LPR120017490/section/abstract_38">http://www.dekker.com/servlet/product/DOI/101081LPR120017490/section/abstract_38</a>
	3A	R.J.H. Stenekes et al., "Degradable dextran microspheres for the controlled release of liposomes", <i>Int. J. Pharmaceutics</i> , <b>214</b> , 17-20 (2001)
	4A	D. Reimer et al., "Cyclosporin (CSA) release from microemulsion: effect of membrane apposition", CSPS 5 <sup>th</sup> Symposium on Pharmaceutical Sciences '02, <i>J. Pharm. Pharmaceut. Sci.</i> ( <a href="http://www.ualberta.ca/~csps">www.ualberta.ca/~csps</a> ), <b>5</b> (2), 39-122 (2002)

EXAMINER'S SIGNATURE	DATE CONSIDERED

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered.  
 Include copy of this form in next communication to applicant.

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).